Boston Scientific no longer expects to launch a transcatheter aortic valve replacement (TAVR) system in the US in 2024, CEO Michael Mahoney said during the company’s fourth-quarter 2023 earnings call on 31 January.
Since discontinuing its Lotus Edge TAVR system in 2020, Boston Scientific has projected it would launch the Acurate neo2 TAVR...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?